饶 勇  共产党员  研究员  博士/硕士生导师，药学院测试中心主任

  邮箱： raoyong0805@126.com

  1.教育背景

  2006.9-2010.6  湖北师范大学 生命科学学院 理学学士

   2010.9-2013.6  广东医科大学 基础医学院 医学硕士

   2013.9-2016.6 中山大学 药学院 理学博士

   2016.7-2021.7 中山大学 药学院 副研究员

   2021.8起    太阳集团tyc5997 研究员

  2. 科研情况

主持项目6项，包括国家自然科学基金青年项目、国家自然科学基金地区基金项目、海南省自然科学基金面上项目等。以项目第一参与人参与科研项目总经费约900万，包括国家自然科学基金重点项目、面上项目、广州市民生科技重大专项等。已发表SCI论文20多篇，其中一作/通讯（含）论文18篇，中科院一区论文14篇；申请/授权专利6项，PCT专利3项。

3. 研究领域

慢性脂肪性肝病与神经退行性疾病分子药理学与创新药物研究；

线粒体代谢调控分子药理学研究；

4. 社会兼职

担任J Med Chem, Eur J Med Chem, Brit J Pharmacol，Gut Microbes等期刊审稿人

5. 代表性项目

1）国家自然科学基金地区基金， NASH治疗新靶点ASNS蛋白抑制剂设计合成及其增强肝脏线粒体代谢活性研究，主持

2）国家自然科学基金青年基金，抗非酒精性脂肪性肝炎（NASH）新型先导化合物发现及作用机制研究，主持

3）海南省自然科学基金面上项目，阿片类药物Flupirtine maleate靶向抑制ASNS蛋白调控肝脏糖脂代谢抗MAFLD研究，主持

4）广东省自然科学基金面上项目，新型HSP90抑制剂的设计合成及其调控能量代谢抗非酒精性脂肪性肝炎活性与新机制研究，主持

5）中山大学青年培育项目，苦参碱类新型HSP90抑制剂的设计合成及其抗非酒精性脂肪性肝炎（NASH）应用研究，主持

6）国家自然科学基金重点项目，能量代谢调控新靶点、新机制发现与创新药物研究，第一参与人

6. 代表性成果

2022年SCI文章

1) Qian Zhou, Meiling Le, Yiyi Yang, Wenjuan Wang, Yuqi Huang, Quan Wang, Yijing Tian, Meiyan Jiang, Yong Rao*, Hai-Bin Luo*, Yinuo Wu*. Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: suppression of neuroinflammation by blocking NF-kB transcription regulation and activating cAMP/CREB axis. Acta Pharmaceutica Sinica B, 2022. https://doi.org/10.1016/j.apsb.2022.09.023 (共同通讯作者，IF 14.903)

2) Chan Li, Yao-Hao Xu, Yu-Tao Hu, Xiu Zhou, Zhi-Shu Huang, Ji-Ming Ye, Yong Rao*. Matrine counteracts obesity in mice via inducing adipose thermogenesis by activating HSF1/PGC-1α axis. Pharmacologic Res, 2022, 177: 106316. (通讯作者，IF 10.334)

3) Yong Rao*, Chan Li, Yu-Tao Hu, Yao-Hao Xu, Bing-Bing Song, Shi-Yao Guo, Zhi Jiang, Dan-Dan Zhao, Shuo-Bin Chen, Jia-Heng Tan, Shi-Liang Huang, Qing-Jiang Li, Xiao-Jun Wang, Ying-Jun Zhang, Ji-Ming Ye, Zhi-Shu Huang*. A novel HSF1 activator ameliorates non-alcoholic steatohepatitis by stimulating mitochondrial adaptive oxidation. Br J Pharmacol, 2022, 179, 1411-1432. (第一作者/共同通讯作者，IF 9.473)

4) Yong Rao*, Chan Li, Yao-Hao Xu, Yu-Tao Hu, Xiu Zhou, Darren C Henstridge, Zhi-Shu Huang*, Ji-Ming Ye*. Activation of HSP72/PRDX6 axis by matrine enhances mitophagy to protect against MAFLD in mice. Br J Pharmacol, 2022. (2^nd修订，第一作者/共同通讯作者，IF 9.473)

5) Wen-Di Duan, Jing-Yu Cao, Chao-Yun Cai, Zhi-Rong Yang, Jin-Feng Cui, Tian Lan, You-Nan Chen, Jing Wang, Yong Rao*, Zhi-Shu Huang, Bo Wang*. Xanthone sulfonamide derivatives-A novel series of α-glucosidase inhibitors with different inhibitory types. J Mol Structure, 2022, 1263, 133026. (共同通讯作者，IF 3.841)

6) Xin-Chen Jiang, Fang-Hai Tu, Li-Yuan Wei, Bo-Zheng Wang, Hao Yuan, Jing-Mei Yuan, Yong Rao, Shi-Liang Huang, Qing-Jiang Li, Tian-Miao Ou, Hong-Gen Wang, Jia-Heng Tan, Shuo-Bin Chen*, Zhi-Shu Huang*. Discovery of a Novel G‑Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer. J Med Chem, 2022, 65(18), 12346-12366. (IF 8.039)

7) Fulin Jiang, Juntao Zheng, Yong Rao, Chang Zhang, Zhishu Huang, Min Huang, Guoping Zhong. Determination of IQZ23 in rat plasma using LC-MS/MS: consideration for matrix effect and internal standard interference. Bioanalysis, 2022, 14, 455-465. (IF 2.695)

8) Xin Pan, Teng-yu Mao, Yan-wen Mai, Cheng-cheng Liang, Wei-hao Huang, Yong Rao, Zhi-shu Huang, Shi-liang Huang*. Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy. Molecules, 2022, 27, 561 (IF 4.927)

9) Xue-Long Yan; Yue-Hua Pan; Run-Zhu Fan; Qin-Qin Song; Shen Li; Jia-Luo Huang; Wei Li; Dong Huang; Fang-Yu Yuan; Gui-Hua Tang; Yong Rao*; Zhi-Shu Huang, Shen Yin*. Discovery of the first Raptor (regulatory-associated protein of mTOR) Inhibitor as a New Type of Antiadipogenic Agent. Metabolism. (Under review, 共同通讯作者，IF13.9)

10) Yong Rao*, Rui Su, Xing-Xing Chai, Jin-Jian Li, Chen-Yan Wu, Guan-Yu Yang, Jun-Jie Wu, Zhong-Ping Jiang, Zhi-Kai Guo, Cong-Jun Xu*, Ling Huang*. Pharmacologic inhibition of PLA2/IRE-1α/XBP-1s axis and JNK signaling by marine fungus Aspergillus sp. c1 metabolite prevents MAFLD in mice. Br J Pharmacol, 2022. (第一作者/共同通讯作者，Under review, IF 9.473)

2021年SCI文章

1) Yong Rao^{1, *}, Zhiqi Kuang, ChaN Li, Shiyao Guo, Yaohao Xu, Dandan Zhao, Yutao Hu, Bingbing Song, Zhi Jiang, Zhenhuang Ge, Xiyuan Liu, Chengdao Li, Shuobin Chen, Jiming Ye, Zhishu Huang^*, Yongjun Lu^*. Gut Akkermansia muciniphila ameliorates metabolic dysfunction associated fatty liver disease by regulating the metabolism of L-aspartate via gut liver axis. Gut Microbes. 2021, 13, 1-19. (第一作者/共同通讯作者，IF 10.245)

2020年SCI文章

1) Yong Rao^1，*, Zhao Xu¹, Yu-Tao Hu, Chan Li, Yao-Hao Xu, Qin-Qin Song, et al. Discovery of a promising agent IQZ23 for the treatment of obesity and related metabolic disorders. Eur J Med Chem, 2020, 192, 112172. (第一作者/共同通讯作者，IF 6.514)

2) Chen-Xi Wang, Zi-Lin Zhang, Qi-Kun Yin, Jia-Li Tu, Jia-En Wang, Yao-Hao Xu, Yong Rao, et al. Design, Synthesis, and Evaluation of NewQuinazolinone Derivatives that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors. J Med Chem, 2020, 63, 9752-9772. (IF 7.446)

2019年SCI文章

1) Yong Rao^*, Yu-Ting Lu, Chan Li, Qin‐Qin Song, Yao‐Hao Xu, Zhao Xu, Yu‐Tao Hu, Hong Yu, Lin Gao, Lian‐Quan Gu, Ji‐Ming Ye^*, Zhi‐Shu Huang^*. Bouchardatine analogue alleviates non‐alcoholic hepatic fatty liver disease/non‐alcoholic steatohepatitis in high‐fat fed mice by inhibiting ATP synthase activity. Br J Pharmacol, 2019, 176, 2877-2893. (第一作者/共同通讯作者，IF 8.739)

2) Qin-Qin Song¹, Yong Rao¹, Gui-Hua Tang¹, Zhang-Hua Sun, Jun-Sheng Zhang, Zhi-Shu Huang^*, Sheng Yin^*. Tigliane Diterpenoids as a New Type of Antiadipogenic Agents Inhibit GRα-Dexras1 Axis in Adipocytes. J Med Chem, 2019, 2060-2075. (共同通讯作者，IF 7.446)

3) Yao-Hao Xu, Qin-Qin Song, Chan Li, Yu-Tao Hu, Bing-Bing Song, Ji-Ming Ye, Yong Rao∗, Zhi-Shu Huang. Bouchardatine suppresses rectal cancer in mice by disrupting its metabolic pathways via activating the SIRT1-PGC-1α-UCP2 axis. Eur J Pharmacol, 2019, 854, 328-337. (共同通讯作者，IF 4.432)

4) Wei Li, Ya-Qi Tang, Shi-Xin Chen, Gui-Hua Tang, Li-She Gan, Chan Li, Yong Rao, Zhi-Shu Huang, and Sheng Yin. Euphorhelipanes A and B, Triglyceride-Lowering Euphorbia Diterpenoids with a Bicyclo[4.3.0]nonane Core from Euphorbia helioscopia. J Nat Prod, 2019, 82, 412-416. (IF 4.05)

5) Yao-Hao Xu, Wei Li, Yong Rao*, Zhi-Shu Huang, Sheng Yin *. Pyridocarbazole alkaloids from Ochrosia borbonica: lipid-lowering agents inhibit the cell proliferation and adipogenesis of 3T3-L1 adipocyte via intercalating into supercoiled DNA. Chin J Nat Med, 2019, 17, 663-671. (共同通讯作者，IF 3.0)

2019年之前发表SCI文章

1) Lin Gao, Zhao Xu, Yong Rao*, Yu-Ting Lu, Yu-Tao Hu, Hong Yu, Yao-Hao Xu, et al. Design, synthesis and biological evaluation of novel bouchardatine analogs as potential inhibitors of adipogenesis/lipogenesis in 3T3-L1 adipocytes. Eur J Med Chem., 2018, 147, 90-101. (共同通讯作者，IF6.514)

2) Chao-Yun Cai, Li Rao, Yong Rao, Jin-Xuan Guo, Zhi-Zun Xiao, Jing-Yu Cao, Zhi-Shu Huang, Bo Wang. Analogues of xanthones Chalcones and bis-chalcones as aglucosidase inhibitors and anti-diabetes candidates. Eur J Med Chem., 2018, 147, 90-101. (IF 6.514)

3) Yong Rao, Hong Yu, Lin Gao, Yu-Ting Lu, Zhao Xu, Hong Liu, Lian-Quan Gu, Ji-Ming Ye^*, Zhi-Shu Huang^*. Natural alkaloid bouchardatine ameliorates metabolic disorders in high-fat diet-fed mice by stimulating the sirtuin 1/liver kinase B-1/AMPK axis. Br J Pharmacol., 2017, 174, 2457-2470. (第一作者，IF8.739)

4) Yong Rao¹, Hong Liu¹, Lin Gao, Hong Yu, Tian-Miao Ou, Jia-Heng Tan, Shi-Liang Huang, et al. Synthesis and Biological Evaluation of Novel Bouchardatine Derivatives as Potential Adipogenesis/Lipogenesis Inhibitors for Antiobesity Treatment. J Med Chem., 2015, 58, 9395-9413. 共同第一作者（排第一），IF7.446

5) Yong Rao, Hong Liu, Lin Gao, Hong Yu, Jia-Heng Tan, Tian-Miao Ou, Shi-Liang Huang, Lian-Quan Gu, Ji-Ming Ye, Zhi-Shu Huang. Discovery of natural alkaloid bouchardatine as a novel inhibitor of adipogenesis/lipogenesis in 3T3-L1 adipocytes. Bioorg Med Chem., 2015, 23, 4719-4727. (第一作者，IF3.641)

7.荣誉奖励

2021年8月以海南省高层次人才引进进入太阳集团tyc5997。

       欢迎对科研满怀热情的药学、生物学、基础医学相关人才加入。